

1005 Rec'd PCT/PTO 28 SEP 2005

pet

Attorney Docket No. 5470-371

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Nancy Davis et al.

Confirmation No.: 8732

Application No.: 10/517,083

Filed: December 6, 2004

For: *Improved Alphavirus Vectors Having Attenuated Virion Structural Proteins*

Date: September 28, 2005

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Respectfully submitted,


Karen A. Magri

Registration No. 41,965

Myers Bigel Sibley & Sajovec, P.A.

P. O. Box 37428

Raleigh, North Carolina 27627

Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Customer No. 20792

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10

Express Mail Label No.: EV 675795867 US

Date of Deposit: September 28, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Sheena L. Donnelly

Substitute form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/517,083	
			Filing Date	December 6, 2004	
			First Named Inventor	Nancy Davis	
			Group Art Unit	TBA	
			Examiner Name	TBA	
Sheet	1	of	8	Attorney Docket Number	5470-371

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1.	US-2001/0016199		Johnston et al.	08-23-2001
	2.	US-2003/0232035		Dubensky, Jr. et al.	12-18-2003
	3.	US-2003/0232036		Johnston et al.	12-18-2003
	4.	US-2004/121466		Johnston et al.	06-24-2004
	5.	US-2004/30117		Johnston et al.	02-12-2004
	6.	US-4,650,764		Temin et al.	03-17-1987
	7.	US-5,091,309		Schlesinger et al.	02-25-1992
	8.	US-5,185,440		Davis et al.	02-09-1993
	9.	US-5,217,879		Huang et al.	06-08-1993
	10.	US-5,505,947		Johnston et al.	04-09-1996
	11.	US-5,639,650		Johnston et al.	06-17-1997
	12.	US-5,643,576		Johnston et al.	07/01/1997
	13.	US-5,739,026		Garoff et al.	04-14-1998
	14.	US-5,766,602		Xiong et al.	01-01-2000
	15.	US-5,789,245		Dubensky et al.	04-04-1998
	16.	US-5,792,462		Johnston et al.	08/11/1998
	17.	US-5,811,407		Johnston et al.	09-22-1998
	18.	US-5,814,482		Dubensky, Jr. et al.	09-29-1998
	19.	US-5,843,723		Dubensky, Jr. et al.	12-01-1998
	20.	US-5,951,975		Falo, Jr. et al.	08-01-1999
	21.	US-5,994,126		Steinman et al.	11-30-1999
	22.	US-6,004,807		Banchereau et al.	12-21-1999
	23.	US-6,008,035		Johnston et al.	12-28-1999
	24.	US-6,015,694		Dubensky et al.	01-01-2000
	25.	US-6,156,304		Glorioso et al.	12-05-2000
	26.	US-6,156,558		Johnston et al.	12-05-2000
	27.	US-6,190,666		Garoff et al.	02-20-2001
	28.	US-6,224,879		Sjöberg et al.	05-01-2001
	29.	US-6,242,259		Polo et al.	06-05-2001
	30.	US-6,468,982		Weiner et al.	10-01-2002
	31.	US-6,521,235		Johnston et al.	02-18-2003
	32.	US-6,531,135		Johnston et al.	03-11-2003
	33.	US-6,541,010		Johnston et al.	04-01-2003
	34.	US-6,583,121		Johnston et al.	06-24-2003
	35.	US-6,844,188		MacDonald et al.	01-18-2005

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/517,083
				Filing Date	December 6, 2004
				First Named Inventor	Nancy Davis
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	8	Attorney Docket Number	5470-371

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
	36.	EP	0 659 885		Akzo Nobel N.V.	12-15-1994	
	37.	WO	1992/10578		Bioption AB	06-25-1992	
	38.	WO	1995/07994		Viagene Inc.	03-23-1995	
	39.	WO	1995/27044		Bioption AB	10-12-1995	
	40.	WO	1995/31565		Bioption AB	11-23-1995	
	41.	WO	1995/32733		U. North Carolina	12-07-1995	
	42.	WO	1996/17072		Viagene Inc.	06-06-1996	
	43.	WO	1996/21416		Viagene Inc.	07-01-1996	
	44.	WO	1996/37220		U. North Carolina	11-28-1996	
	45.	WO	1996/37616		U. North Carolina	11-28-1996	
	46.	WO	1997/24447		Viagene Inc.	07-01-1997	
	47.	WO	1997/38087		Viagene Inc.	10-16-1997	
	48.	WO	1998/00163		U. of Pittsburgh	01-01-1998	
	49.	WO	1998/36779		U. North Carolina	08-27-1998	
	50.	WO	1999/30734		Searle & Co.	06-01-1999	
	51.	WO	1999/51263		U. North Carolina	10-14-1999	
	52.	WO	2000/39318		Chiron Corp.	07-06-2000	
	53.	WO	2001/16343		U. North Carolina	03-08-2001	
	54.	WO	2001/47456		Kimberly Clark Co.	07-05-2001	
	55.	WO	2002/20721		U. North Carolina	03-14-2002	
	56.	WO	2003/083065		U. North Carolina	10-09-2003	

OTHER NON PATENT LITERATURE DOCUMENTS					T
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	57.	"Program and Abstracts of the Joint Annual Meeting of the American Society of Tropical Medicine and Hygiene and the American Society of Parasitologists" <i>Supplement to the American Journal of Tropical Medicine and Hygiene</i> 49(3): (1993)			
	58.	"Sindbis Virus (HRSP and Wild-Type Strains), Complete Genome," <i>EMBL Database, Accession Numbers J02363, 02364, J02366, J02367, and V00073, (July 3, 1991).</i>			
	59.	BARRETT et al. "Antibody-mediated Early Death <i>in vivo</i> after Infection with Yellow Fever Virus." <i>Journal of General Virology</i> 67:2530-2542 (1986).			
	60.	BERGE et al., "Studies on the virus of venezuelan equine encephalomyelitis," <i>Journal of Immunology</i> , 87: 509-517 (1961).			
	61.	BERNARD et al. "Mutations in the E2 Glycoprotein of Venezuelan Equine Encephalitis Virus Confer Heparan Sulfate Interaction, Low Morbidity, and Rapid Clearance from Blood of Mice" <i>Virology</i> 276: 93-103 (2000)			
	62.	BOWERS et al. "Dendritic cell ontogeny." <i>Research in Immunology</i> 140(9): 880-883 (1989).			
	63.	BREDENBEEK et al, <i>Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using</i>			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/517,083
		Filing Date	December 6, 2004
		First Named Inventor	Nancy Davis
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet	3	of	8
		Attorney Docket Number	5470-371

		<i>Defective Helper RNAs, Journal of Virology</i> 67 No. 11, pp. 6439-6446 (1993).	
64.	BULYCHYOV et al., "Disease Course in Guinea Pigs After Aerogenous Infection with Venezuelan Equine Encephalomyelitis virus," (1995).		English Abstract
65.	CALEY et al. "Hormonal, Mucosal and Cellular Immunity in Response to a Human Immunodeficiency Virus Type 1 immunogen Expressed by a Venezuelan Equine Encephalitis Virus Vaccine Vector" <i>Journal of Virology</i> 71(4): 3031-3038 (1997)		
66.	CHANAS et al. "Monoclonal Antibodies to Sindbis Virus Glycoprotein E1 can Neutralize, Enhance Infectivity, and Independently Inhibit Haemagglutination or Haemolysis." <i>Journal of General Virology</i> 58:37-46 (1982).		
67.	CORSINI et al.: <i>Efficiency of Transduction by Recombinant Sindbis Replicon Virus Varies Among Cell Lines, Including Mosquito Cells and Rat Sensory Neurons</i> , BioTechniques, 21:3 (492-497), September 1996.		
68.	DAVIS et al, <i>A Genetically Engineered Live Virus Vaccine for Venezuelan Equine Encephalitis</i> ; <i>J. Cell Biochemistry Supplement</i> O No. 17 Part D, issued 1993, Abstract N404.		
69.	DAVIS et al, <i>Attenuated Mutants of Venezuelan Equine Encephalitis Virus Containing Lethal Mutations in the PE2 Cleavage Signal Combined with a Second-Site Suppressor Mutation in E1</i> , <i>Virology</i> 212:102-110 (1995).		
70.	DAVIS et al. "Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles." <i>Journal of Virology</i> 74(1):371-378 (2000).		
71.	DAVIS et al. "A Viral Vaccine Vector that Expresses Foreign Genes in Lymph Nodes and protects Against Mucosal Challenge" <i>Journal of Virology</i> 70(6): 3781-3787 (1996)		
72.	DAVIS et al. "An Attenuated VEE Virus Vaccine Vector: Expression of HIV-1 and Influenza Genes in Cell Culture and Protection Against Influenza Challenge in Mice Immunized with a Vector Expressing HA" <i>Vaccines</i> 95:387-391 (1995)		
73.	Davis et al. "In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNAs from a cDNA Clone: Analysis of a Viable Deletion Mutant" <i>Virology</i> 171: 189-204 (1989)		
74.	DAVIS et al., <i>Attenuating Mutations in the E2 Glycoprotein Gene of Venezuelan Equine Encephalitis Virus: Construction of Single and Multiple Mutants in a Full-Length cDNA Clone</i> , <i>Virology</i> 183 20-31 (1991).		
75.	DAVIS et al; In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant and Mutations Affecting Virulence, <i>Vaccines</i> 90, pp. 109-113 (1990).		
76.	DE VEERMAN et al. "Retrovirally Transduced Bone Marrow-Derived Dendritic Cells Require CD4,sup.+ T Cell Help to Elicit Protective and Therapeutic Antitumor Immunity" <i>The Journal of Immunology</i> 162: 144-151 (1999)		
77.	DIETZ et al. "High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells" <i>Blood</i> 91(2): 392-398 (1998)		
78.	DISIS et al. <i>Journal of Immunology</i> 156: 3151-3158 (1996)		
79.	DUBENSKY Jr. et al. "Sindbis Virus DNA-Based Expression Vectors: Utility for in Vitro and in Vivo Gene Transfer," <i>Journal of Virology</i> , 70:1 508-519 (January 1996).		
80.	ENGLER et al; Venezuelan Equine Encephalitis-Specific Immunoglobulin Responses: Live Attenuated TC-83 Versus Inactivated C-84 Vaccine; <i>Journal of Medical Virology</i> 38, pp. 305-310 (1992).		
81.	FLYNN et al. "Antibody-Mediated Activation of Sindbis Virus." <i>Virology</i> 166:82-90 (1988).		
82.	Frolov et al. "Recombinant Venezuelan Equine Encephalomyelitis Viruses Expressing HBsAg" <i>Papers of the Academy of Science</i> 332(6): 789-781 (1993)		Yes

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/517,083	
			Filing Date	December 6, 2004	
			First Named Inventor	Nancy Davis	
			Group Art Unit	TBA	
			Examiner Name	TBA	
Sheet	4	of	8	Attorney Docket Number	5470-371

83.	FROLOV et al., "Translation of Sindbis Virus in RNA: Effects of Sequences Downstream of the Initiating Codon," <i>Journal of Virology</i> , 68 8111-end (1994).
84.	FROLOV et al., "Translation of Sindbis Virus mRNA: Analysis of Sequences Downstream of the Initiating AUG Codon That Enhance Translation," <i>Journal of Virology</i> 70(2): 1182-1190 (1996).
85.	FROLOV et al., <i>Alphavirus-based expression vectors: Strategies and applications</i> , <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 11371-11377 (1996).
86.	FROLOV et al; Comparison of the Amino Acid Sequences of Structural Proteins of Attenuated and Pathogenic Strains of Venezuelan Equine Encephalomyelitis Virus, <i>Doklady Biochemistry</i> 318, pp. 144-146 (1991).
87.	FROLOV et al; Influence of Mutations in Genes of the Structural Proteins of Venezuelan Equine Encephalomyelitis on its Attenuation, <i>Doklady Biological Sciences</i> 326 pp. 466-469 (1992).
88.	FROLOV et al; Recombinant VEE Virus Expresses HBsAg, <i>Proceedings, IXth International Congress of Virology</i> , p. 67 (Aug. 8-13, 1993) (Abstract)
89.	FROLOVA et al., "Packaging Signals in Alphaviruses," <i>Journal of Virology</i> , 71 248-258 (January 1997).
90.	FÜST "Enhancing antibodies in HIV infection." <i>Parasitology Supplemental</i> 115:127-140 (1997).
91.	GALILI et al. "Natural Anti-Gal Antibody as a Universal Augmenter of Autologous Tumor Vaccine Immunogenicity" <i>Immunology Today</i> 18(6): 281-285 (1997)
92.	GARDNER et al. "Infection of human Dendritic Cells by a Sindbis Virus Replicon Vector is Determined by a Single Amino Acid Substitution in the E2 Glycoprotein" <i>Journal of Virology</i> 74(24): 11849-11857 (2000)
93.	GEIGENMULLER-GNIRKE et al. "Complementation Between Sindbis Viral RNAs Produces Infectious Particles with a Bipartite Genome." <i>Proceedings of the National Academy of Sciences of the United States of America</i> , Vol. 88, Issue 8 (April 15, 1991), 3253-3257.
94.	GLASGOW et al; "A single amino acid change in the E2 spike protein of a virulent strain of Semliki Forest virus attenuates pathogenicity" <i>Journal of General Virology</i> 75 pp. 663-668 (1994).
95.	GLASGOW et al; Two Mutations in the Envelope Glycoprotein E2 of Semliki Forest Virus Affecting the Maturation and Entry Patterns of the Virus Alter Pathogenicity for Mice; <i>Virology</i> 185, pp. 741-748 (1991).
96.	GRIEDER et al., <i>Specific Restrictions in the Progression of Venezuelan Equine Encephalitis Virus-Induced Disease Resulting from Single Amino Acid Changes in the Glycoproteins</i> , <i>Virology</i> , 206, pp. 994-1006 (1995).
97.	GUYRE et al. "Increased potency of Fc-receptor-targeted antigens." <i>Cancer Immunology, Immunotherapy</i> 45:146-148 (1997).
98.	HAHN et al., "Infectious Sindbis Virus Transient Expression Vectors for Studying Antigen Processing and Presentation," <i>Proc. Natl. Acad. Sci. USA</i> , 89 2679-2683 (1992).
99.	HAWKES et al. "The Enhancement of Virus Infectivity by Antibody." <i>Virology</i> 33:250-261 (1967).
100.	HEIDNER et al; Lethality of PE2 Incorporation into Sindbis Virus Can Be Suppressed by Second-Site Mutations in E3 and E2; <i>Journal of Virology</i> , 68 No. 4, pp. 2683-2692 (1994).
101.	HEISE et al., "A Single Amino Acid Change in nsP1 Attenuates Neurovirulence of the Sindbis-Group Alphavirus S.A.AR86," <i>Journal of Virology</i> , 74:9 (May 2000).
102.	HEISE et al., "Adult Mouse Neurovirulence Determinants Within the Nonstructural Genes of the Sindbis-Group Alphavirus S.A.AR86," <i>American Society of Virology Meeting, Colorado</i> , Oral

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/517,083	
			Filing Date	December 6, 2004	
			First Named Inventor	Nancy Davis	
			Group Art Unit	TBA	
			Examiner Name	TBA	
Sheet	5	of	8	Attorney Docket Number	5470-371

		Presentation (July 11, 2000).	
	103.	HEISE et al., "Sindbis-Group Alphavirus Replication in Periosteum and Endosteum of Long Bones in Adult Mice," <i>Journal of Virology</i> , 74:19 9294-9299 (October 2000 – published on-line September 11, 2000).	
	104.	HEISE et al., "The Role of Viral Nonstructural Genes in Neurovirulence of the Sindbis-Group Virus, S.A.AR86," <i>Keystone Symposia, Taos, New Mexico</i> , 306 (February 2000).	
	105.	HEUFLE, Christine, et al. "Granulocyte/Macrophage Colony-Stimulating Factor and Interleukin 1 Mediate the Maturation of Murine Epidermal Langerhans Cells into Potent Immunostimulatory Dendritic Cells." <i>Journal of Experimental Medicine</i> 167(February):700-705 (1988).	
	106.	HODGSON et al., "Expression of Venezuelan Equine Encephalitis Virus Proteins by Recombinant Baculoviruses," <i>The American Journal of Tropical Medicine and Hygiene</i> , 49:3. 195-196 (1993) (Abstract)	
	107.	IKONOMIDIS et al. "Influenza-Specific Immunity Induced by Recombinant <i>Listeria monocytogenes</i> Vaccines" <i>Vaccines</i> 15(4): 433-440 (1997)	
	108.	INADA, T. & C.A. Mims "Association of Virulence of Murine Cytomegalovirus with Macrophage Susceptibility and with Virion-bound Non-neutralizing Antibody." <i>Journal of General Virology</i> 66:879-882 (1985).	
	109.	INADA, T. et al. "Enhancing Antibodies, Macrophages and Virulence in Mouse Cytomegalovirus Infection." <i>Journal of General Virology</i> 66:871-878 (1985).	
	110.	International Search Report for PCT/US03/19626 on December 30, 2004	
	111.	JOHNSTON et al. "Alphavirus Vectors: Biology and Vaccine Potential" Abstract and slide list <i>ECEAR Meeting</i> Edinburgh, Scotland (June 2001)	
	112.	JOHNSTON, "Alphavirus Expression Vectors: Potential Applications for Gene Expression, Vaccines and Gene Therapy," slide list, <i>Presentation to the Scientific Advisory Board of OraVax, Inc.</i> Boston, MA (March 31, 1997).	
	113.	KAWAKAMI et al. "Section 3.1 Genes coding for Tumor Antigens Recognized by T Lymphocytes" <i>Biological Therapy of Cancer</i> 2nd Edition pp. 53-63 J.B. Lippincott Company (1995)	
	114.	KINNEY et al; The Full-Length Nucleotide Sequence of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and Its Attenuated Vaccine Derivative, Strain TC-83; <i>Virology</i> 170, pp. 19-30 (1989).	
	115.	KINNEY, Richard, "Attenuation of Venezuelan Equine Encephalitis Virus Strain TC-83 Is Encoded by the 5'-Noncoding Region and the E2 Envelope Glycoprotein." <i>Journal of Virology</i> . Vol. 67, No. 3, (March 1993), 1269-1277.	
	116.	LEMM et al., <i>Polypeptide requirements for assembly of functional Sindbis virus replication complexes: a model for the temporal regulation of minus- and plus-strand RNA synthesis</i> , <i>The EMBO Journal</i> , Vol. 13, No. 12, pp. 2925-2934 (1994).	
	117.	LILJESTRÖM et al., <i>A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon</i> , <i>Bio/Technology</i> , Vol. 9, December 1991, pp. 1356-1361.	
	118.	LILJESTRÖM, Peter, "Alphavirus expression systems." <i>Current Opinion in Biotechnology</i> . Vol. 5, No. 5, (October 1994), 495-500.	
	119.	LILJESTRÖM, Peter, "Alphavirus Vectors for Gene Delivery," <i>OECD Documents, Gene Delivery Systems</i> , 109-118 (1996).	
	120.	LINN et al., "Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis," <i>J. Gen. Virol.</i> 77: 407-411 (1996).	
	121.	LONDON et al., "Infectious Enveloped RNA Virus Antigenic Chimeras," <i>Proc. Natl. Acad. Sci. USA</i> , 89 207-211 (1992).	
	122.	LVOV et al., "'Karshi' Virus, a New Flavivirus (Togaviridae) Isolated from <i>Ornithodoros Papillipes</i> (Birula, 1895) Ticks in Uzbek S.S.R.," <i>Archives of Virology</i> , 50 29-36 (1976).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/517,083	
			Filing Date	December 6, 2004	
			First Named Inventor	Nancy Davis	
			Group Art Unit	TBA	
			Examiner Name	TBA	
Sheet	6	of	8	Attorney Docket Number	5470-371

123.	MACDONALD, Gene H. & Robert E. Johnston "Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis." <u>Journal of Virology</u> 74(2):914-922 (2000).	
124.	MADY, Brian J., et al. "Neuraminidase augments Fcy receptor II-mediated antibody-dependent enhancement of dengue virus infection." <u>Journal of General Virology</u> 74:839-844 (1993).	
125.	MCKENZIE, Steven E. "Biological advances and clinical application of Fc receptors for IgG." <u>Current Opinion in Hematology</u> 1:45-52 (1994).	
126.	MCKNIGHT et al., "Deduced Consensus Sequences of Sindbis Virus Strain AR339: Mutations Contained in Laboratory Strains which Affect Cell Culture and in Vivo Phenotypes," <u>Journal of Virology</u> , 70(3) 1981-1989 (1996).	
127.	MORENS, David M. "Antibody-Dependent Enhancement of Infection and the Pathogenesis of Viral Disease." <u>Clinical Infectious Diseases</u> 19:500-512 (1994).	
128.	MORENS, David M. & S.B. Halstead "Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies." <u>Journal of General Virology</u> 71:2909-2914 (1990).	
129.	MORGENSTEIN et al, <i>Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line</i> , <u>Nucleic Acids Research</u> 18:No. 12, pp. 3587-3596 (1990).	
130.	NADLER et al., "Monoclonal antibody identifies a new Ia-like (p29,34) polymorphic system linked to the HLA-D/DR region," <u>Nature</u> 290: 591 (1981).	
131.	OCHIAI, Hiroshi, et al. "Infection Enhancement of Influenza A NWS Virus in Primary Murine Macrophages by Anti-Hemagglutinin Monoclonal Antibody." <u>Journal of Medical Virology</u> 36:217-221 (1992).	
132.	OLSEN, "A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination," <u>Veterinary Microbiology</u> 36: 1-37 (1993).	
133.	ORKIN et al., "Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy," 1-41 (1995).	
134.	PAN et al. "A Recombinant Listeria Monocytogenes Vaccine Expressing a Model Tumour Antigen Protects Mice Against Lethal Tumour Cell Challenge and Causes Regression of Established Tumors" <u>Nature Medicine</u> 1(5): 471-477 (1995)	
135.	PAN et al.; <i>Regression of Established Tumors in Mice Mediated by the Oral Administration of a Recombinant Listeria monocytogenes Vaccine</i> , <u>Cancer Research</u> 55:4776-4779 (1995).	
136.	Peiris, J.S.M. J.S. Porterfield "Antibody-dependent Enhancement of Plaque Formation on Cell Lines of Macrophage Origin-A Sensitive Assay for Antiviral Antibody." <u>Journal of General Virology</u> 57:119-125 (1981).	
137.	PEIRIS, J.S.M. et al. "Monoclonal anti-FC receptor IgG blocks antibody enhancement of viral replication in macrophages." <u>Nature</u> 289(January 15 th):189-191 (1981).	
138.	Polo et al. "Molecular Analysis of Sindbis Virus Pathogenesis in Neonatal Mice by using Virus Recombinants Constructed In Vitro" <u>Journal of Virology</u> 62: 2124-2133 (1988)	
139.	POLO et al., <i>Attenuating Mutations in Glycoproteins E1 and E2 of Sindbis Virus Produce a Highly Attenuated Strain When Combined in Vitro</i> , <u>Journal of Virology</u> 64 No. 9, pp. 4438-4444 (1990).	
140.	PORTERFIELD, "Antibody-dependent Enhancement of Viral Infectivity," <u>Advances in Virus Research</u> 31: 335-354 (1986).	
141.	RAABE et al., "In Vitro Antibody-Dependent Enhancement Assays are Insensitive Indicators of <i>in Vivo</i> Vaccine Enhancement of Equine Infectious Anemia Virus," <u>Virology</u> 259: 416-427 (1999).	
142.	RESTIFO et al.; <i>Transfectant Influenza A Viruses Are Effective Recombinant Immunogens in the Treatment of Experimental Cancer</i> , <u>Virology</u> 249:89-97 (1998).	
143.	RESTIFO; <i>The new vaccines: building viruses that elicit antitumor immunity</i> , <u>Current Opinion in Immunology</u> , 9:658-663 (1997).	
144.	ROSENBERG; <i>A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer</i>	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/517,083	
			Filing Date	December 6, 2004	
			First Named Inventor	Nancy Davis	
			Group Art Unit	TBA	
			Examiner Name	TBA	
Sheet	7	of	8	Attorney Docket Number	5470-371

		<i>Antigens, Immunity</i> 10:281-287 (1999).	
145.	RUSSELL et al., <i>Sindbis Virus Mutations Which Coordinately Affect Glycoprotein Processing, Penetration, and Virulence in Mice</i> , <i>Journal of Virology</i> , Vol. 63, No. 4, April 1989, pp. 1619-1629.		
146.	SCHLESINGER et al., "Recombination between Sindbis virus RNAs." <i>Archives of Virology</i> . Suppl. 9, (1994), 213-220.		
147.	SCHLESINGER, Jacob J. Michael W. Brandriss "17D Yellow Fever Virus Infection of P388D ₁ Cells Mediated by Monoclonal Antibodies; Properties of the Macrophage Fc Receptor," <i>Journal of General Virology</i> 64: 1255-1262 (1983).		
148.	SCHLESINGER, Sondra, "Alphaviruses - vectors for the expression of heterologous genes." <i>TiBTech.</i> (1993), 18-22.		
149.	SCHOEPP et al., <i>Directed Mutagenesis of a Sindbis Virus Pathogenesis Site</i> ; <i>Virology</i> 193, pp. 149-159 (1993).		
150.	SCHULER et al.; <i>Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors</i> , J. Exp. Med. 186:8 1183-1187 (1997).		
151.	SIMPSON et al., "Sindbis-Like Virus Isolate Girdwood S.A., Complete Genome," <i>EMBL Database</i> , Accession Number U38304, (January 3, 1996).		
152.	SIMPSON et al., <i>Complete Nucleotide Sequence and Full-Length cDNA Clone of S.A.AR86, a South African Alphavirus Related to Sindbis</i> , <i>Virology</i> 222 (464-469) Article No. 0445, 1996.		
153.	SJOBERG et al. "A Significantly Improved Semliki Forest Virus Expression System Based on Translation Enhancer Segments from the Viral Capsid Gene" <i>Bio/Technology</i> 12: 1127-1131 (1994)		
154.	SONG et al.; <i>Antigen presentation in retroviral vector-mediated gene transfer in vivo</i> , Proc. Natl. Acad. Sci. USA 94:1943-1948 (1997).		
155.	SONG et al.; <i>Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity</i> , J. Exp. Med. 186:8 1247-1256 (1997).		
156.	SPECHT et al.; <i>Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases</i> , J. Exp. Med. 186:8 1213-1221 (1997).		
157.	STEINMAN, "The Dendritic Cell System and its Role in Immunogenictiy." <i>Annual Review of Immunology</i> . 9: 271-296 (1991).		
158.	STORKUS et al.; Section 3.2 <i>Tumor Antigens Recognized by Immune Cells</i> , Biologic Therapy of Cancer Second Edition, J.B. Lippincott Company, 1995 pp. 64-77.		
159.	STRAUSS et al. "The Alphaviruses: Gene Expression, Replication, and Evolution" <i>Microbiological Reviews</i> pp. 491-562 (1994)		
160.	SUOMALAINEN et al. "Spike Protein-Nucleocapsid Interactions Drive the Budding of Alphaviruses" <i>Journal of Virology</i> 66(8): 4737-4747 (1992)		
161.	VENNEMA et al., "Early Death after Feline Infectious Peritonitis Virus Challenge due to Recombinant Vaccinia Virus Immunization," <i>Journal of Virology</i> 64(3): 1407-1409 (1990).		
162.	VRATI et al; Ross River Virus Mutant with a Deletion in the E2 Gene: Properties of the Virion, Virus-Specific Macromolecule Synthesis, and Attenuation of Virulence for Mice; <i>Virology</i> 151 pp. 222-232 (1986).		
163.	WANG et al.; <i>Active Immunotherapy of Cancer with a Nonreplicating Recombinant Fowlpox Virus Encoding a Model Tumor Associated Antigen</i> , <i>The Journal of Immunology</i> 154:4685-4692 (1995).		
164.	WEISS et al. "Recombination Between Sindbis Virus RNAs" <i>Journal of Virology</i> 65(8): 4017-4025 (1991)		
165.	WEST et al. "Genetic Analysis of Cell Targeting and Immunogenicity of VEE Vectors" Abstract <i>AIDS Vaccine 2001 Meeting Philadelphia, PA</i> (September 2001)		
166.	WU et al.; <i>Tolerance to a Dominant T Cell Epitope in the Acetylcholine Receptor Molecule Induces</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/517,083
				Filing Date	December 6, 2004
				First Named Inventor	Nancy Davis
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	8	of	8	Attorney Docket Number	5470-371

		<i>Epitope Spread and Suppresses Murine Myasthenia Gravis</i> , The Journal of Immunology 159 :6 3016-3023 (1997).	
	167.	XIONG et al. "Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells" <i>Science</i> 243(4895): 1188-1191 (1989)	
	168.	XP002157462, <i>CD Antigen designations</i> , http://www.amb.casaccia.enea.it/glc/CD-table.htm , (1995).	
	169.	YAO et al., "Antibody-dependent enhancement of hantavirus infection in macrophage cell lines," <i>Archives of Virology</i> 122: 107-118 (1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.